TMCnet News
Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022BRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the 2022 RHK Capital Disruptive Growth Conference hosted at Reed Smith in New York City on December 5-6, 2022. Mr. Randy Milby, Founder and Chief Executive Officer of Hillstream BioPharma will present on Tuesday December 6th at 11:40 am ET. Mr. Milby will be available for one-on-one meetings and also for additional appointments with members of the investment community. The presentation will be webcast. To access the live webcast and subsequent archived recordings for the presentation, please visit the Hillstream BioPharma website at: www.hillstreambio.com. To register for the conference and participate in 1-on-1 meetings please click this link, www.DisruptNYC.com “We look forward to the opportunity to participate in this conference to discuss our game changing cance fighting treatment methodology with a broad scope of individuals,” said Mr. Milby. “Additionally, this event will allow us to network with other key players in the drug development industry.” About the RHK Capital Disruptive Growth Conference About RHK Capital RHK Capital is a pioneer in the revival and re-purpose of the rights offering structure, with additional experience in warrant offerings, IPOs, primary offerings, follow-on offerings, registered directs, confidentially marketed public offerings, private placements, secondaries, exchange offers, mergers and acquisitions, stock and asset sales, restructurings, recapitalization and other related investment banking activities. Richard H. Kreger and Bruce Ryan co-founded RHK Capital. About Hillstream BioPharma Inc. Investor Relations Contact: |